| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.510310209 |
| P698 | PubMed publication ID | 10655252 |
| P2093 | author name string | Smith C | |
| Jorgensen RA | |||
| Angulo P | |||
| Lindor KD | |||
| Dickson ER | |||
| Keach JC | |||
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| Serum bilirubin: a prognostic factor in primary biliary cirrhosis | Q34494336 | ||
| Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy. | Q40869624 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Ultrastructural and immunohistochemical studies of the intrahepatic peribiliary capillary plexus in normal livers and extrahepatic biliary obstruction in human beings | Q42459670 | ||
| Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability | Q43475774 | ||
| Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid | Q43893454 | ||
| The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis | Q45024371 | ||
| A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants | Q46206581 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. | Q53843390 | ||
| Oral budesonide for treatment of autoimmune chronic active hepatitis | Q54020669 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management | Q60530953 | ||
| A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results | Q67590480 | ||
| Factors of prognostic importance in primary biliary cirrhosis | Q68712203 | ||
| A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss | Q69721905 | ||
| Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis | Q71035932 | ||
| A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group | Q71748735 | ||
| Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone | Q72227193 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone | Q73574823 | ||
| Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis | Q74529900 | ||
| Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group | Q77164841 | ||
| Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group | Q77349947 | ||
| Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis | Q77716502 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol | Q78039881 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 318-323 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | |
| P478 | volume | 31 |
| Q36851472 | A case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab |
| Q26771816 | A review of the medical treatment of primary sclerosing cholangitis in the 21st century |
| Q39293482 | Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid |
| Q46925344 | Autoimmune Hepatitis – Primary Biliary Cirrhosis Overlap Syndrome |
| Q42620850 | Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid |
| Q45309693 | Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial |
| Q33709930 | Clinical application of transcriptional activators of bile salt transporters |
| Q37182934 | Clinical features and management of primary biliary cirrhosis. |
| Q36330872 | Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells |
| Q36752084 | Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q35068031 | Current management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q34408950 | Current status of therapy in autoimmune liver disease |
| Q34687676 | Drug therapy of primary biliary diseases: classical and modern strategies. |
| Q92864604 | Emerging therapies for PBC |
| Q41813541 | Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis |
| Q24244255 | Glucocorticosteroids for primary biliary cirrhosis |
| Q43807982 | Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? |
| Q81724957 | Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q50130002 | Modern treatment of primary biliary cholangitis |
| Q37355843 | Natural history and management of primary biliary cirrhosis |
| Q92135848 | New Therapeutic Targets in Autoimmune Cholangiopathies |
| Q38261577 | New therapies for primary biliary cirrhosis |
| Q38342107 | Novel therapeutic targets in primary biliary cirrhosis |
| Q36786270 | Nuclear receptors as drug targets in cholestatic liver diseases |
| Q34354186 | Options for treatment of primary biliary cirrhosis |
| Q90707736 | Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases |
| Q39047912 | Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics |
| Q54390436 | Primary biliary cholangitis: new treatments for an old disease. |
| Q21202919 | Primary biliary cirrhosis |
| Q56428273 | Primary biliary cirrhosis |
| Q56854243 | Primary biliary cirrhosis |
| Q26853649 | Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy |
| Q35894578 | Primary biliary cirrhosis: report of a focus study group |
| Q35573929 | Primary biliary cirrhosis: specific treatment |
| Q35573937 | Primary biliary cirrhosis: the future |
| Q37072380 | Proposed therapies in primary biliary cholangitis |
| Q44004769 | Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis |
| Q42406650 | Recent developments in the management of idiopathic cholestatic liver disease |
| Q36574505 | Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management. |
| Q42376792 | Risk and adverse outcomes of fractures in patients with liver cirrhosis: two nationwide retrospective cohort studies |
| Q38129543 | Roux-en-Y choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis: a meta-analysis |
| Q36180465 | Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. |
| Q52624982 | The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. |
| Q35833175 | The diagnosis and treatment of primary biliary cirrhosis |
| Q34182672 | Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q34398020 | Treatment of primary biliary cirrhosis |
| Q64991757 | Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? |
| Q55333522 | Update on pharmacotherapies for cholestatic liver disease. |
Search more.